May 7th 2024
Data from the phase 3 CRC-PREVENT trial support the sensitivity of ColoSense in the detection of colorectal cancer.
Medical Crossfire®: Critical Questions on Diagnosis, Sequencing, and Selection of Systemic and Radioligand Therapy Options for Patients with GEP-NETs
View More
Community Practice Connections™: 8th Annual School of Gastrointestinal Oncology®
View More
2024 International Symposium of Gastrointestinal Oncology (ISGIO)
October 11-12, 2024
Register Now!
Community Practice Connections™: 5th Annual Precision Medicine Symposium – An Illustrated Tumor Board
View More
Community Oncology Connections™: Overcoming Barriers to Testing, Trial Access, and Equitable Care in Cancer
View More
The Next Wave in Biliary Tract Cancers: Leveraging Immunogenicity to Optimize Patient Outcomes in an Evolving Treatment Landscape
View More
Community Practice Connections™: 9th Annual School of Gastrointestinal Oncology®
View More
Henry Adewoye, MD, on the Phase I Trial of COM701 in Advanced Solid Tumors
April 30th 2020The study was presented at the American Association for Cancer Research (AACR) Annual Virtual Meeting 2020 and demonstrated encouraging preliminary antitumor activity with objective responses as a monotherapy and in combination with nivolumab.
Experts Issue Recommendations for Patients with Rectal Cancer During the COVID-19 Pandemic
April 10th 2020Leading cancer experts from across Europe issued an international expert consensus statement regarding radiotherapy treatment options for patients with rectal cancer during the COVID-19 pandemic.
FDA Grants Priority Review to Pembrolizumab Monotherapy for TMB-High Tumors
April 7th 2020The FDA granted priority review to pembrolizumab monotherapy for the treatment of adult and pediatric patients with unresectable or metastatic TMB-high solid tumors who have progressed following prior treatment and who have no satisfactory alternative treatment options.
Pembrolizumab Induces Significantly Improved PFS in MSI-H/dMMR Colorectal Cancer
April 3rd 2020The trial evaluating the first-line treatment of pembrolizumab in patients with microsatellite instability-high or mismatch repair deficient unresectable or metastatic colorectal cancer demonstrated improved PFS compared with chemotherapy.
Potential for Prognostic Biomarkers in T1 Colorectal Cancer Treatment Selection
March 23rd 2020In this study, researchers found that endoscopic therapy was the most effective strategy for patients with T1 CRC with less aggressive biomarker profiles and laparoscopic colectomy was the most effective for patients with more aggressive profiles.
Early-Onset Gastric Cancer Suggested to be Genetically and Clinically Distinct
January 20th 2020Incidence of early-onset gastric cancer has steadily increased in the US, now comprising >30% of new gastric cancer cases today, causing researchers to try and discover what makes this disease type unique.
Review of Maintenance Treatment in mCRC Highlights Need for Shared Decision Making
January 16th 2020Although researchers determined which regimen was preferred among physicians in treating metastatic colorectal cancer, they found that shared decision-making should include observation as an acceptable option.
Locally Advanced Rectal Cancer, What is the Standard of Care?
A 39-year-old Hispanic male presented with complaints of mucous stools, loss of appetite, rectal bleeding and a 30-pound weight loss within the past several months.
Association of Aspirin Use With Mortality Risk Among Older Adult Patients with Cancer
December 27th 2019The use of aspirin 3 or more times a week was associated with a reduction in all-cause, cancer, gastrointestinal cancer, and colorectal cancer mortality in adults 65 and over, according to a study published in JAMA Network Open.